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Abstract The purpose of this study was to compare the
midterm results of a radiological and surgical approach to
uterine ﬁbroids. One hundred twenty-one women with
reproductive plans who presented with an intramural
ﬁbroid(s) larger than 4 cm were randomly selected for
either uterine artery embolization (UAE) or myomectomy.
We compared the efﬁcacy and safety of the two procedures
and their impact on patient fertility. Fifty-eight emboliza-
tions and 63 myomectomies (42 laparoscopic, 21 open)
were performed. One hundred eighteen patients have ﬁn-
ished at least a 12-month follow-up; the mean follow-up in
the entire study population was 24.9 months. Embolized
patients underwent a signiﬁcantly shorter procedure and
required a shorter hospital stay and recovery period. They
also presented with a lower CRP concentration on the
second day after the procedure (p\0.0001 for all
parameters). There were no signiﬁcant differences between
the two groups in the rate of technical success, symptom-
atic effectiveness, postprocedural follicle stimulating
hormone levels, number of reinterventions for ﬁbroid
recurrence or regrowth, or complication rates. Forty
women after myomectomy and 26 after UAE have tried to
conceive, and of these we registered 50 gestations in 45
women. There were more pregnancies (33) and labors (19)
and fewer abortions (6) after surgery than after emboliza-
tion (17 pregnancies, 5 labors, 9 abortions) (p\0.05).
Obstetrical and perinatal results were similar in both
groups, possibly due to the low number of labors after UAE
to date. We conclude that UAE is less invasive and as
symptomatically effective and safe as myomectomy, but
myomectomy appears to have superior reproductive out-
comes in the ﬁrst 2 years after treatment.
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Uterine ﬁbroid embolization
Embolization of uterine ﬁbroids, which was ﬁrst introduced
by Ravina et al. [1] in 1995, is now a well-established
therapeutic procedure. Uterine artery embolization (UAE)
is mostly performed in women with symptomatic ﬁbroids
who do not plan further pregnancy. Its use in women with
reproductive plans is still controversial. Evidence exists
that there is a possible risk of infection, which may lead to
sepsis and hysterectomy and premature ovarian failure in
these patients [2–4].
Myomectomy is considered to be a standard treatment
procedure for the removal of myomas in patients of fertile
age [5]. This procedure can also be associated with dra-
matic complications such as perioperative bleeding and
uterine rupture during subsequent gravidity, which may
require hysterectomy. We thus decided to compare the
efﬁcacy and safety of these two approaches in women with
reproductive plans who presented with intramural uterine
ﬁbroids. The ﬁrst results of this trial have already been
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Cardiovasc Intervent Radiol (2008) 31:73–85
DOI 10.1007/s00270-007-9195-2published [6]. The aim of this paper is to present midterm
clinical and ﬁrst reproductive results obtained in a larger
group of patients.
Materials and Methods
Trial Design
The trial was approved by the Ethics Committee of the First
Medical Faculty of Charles University. It was designed as
prospective and randomized. Every newly recruited patient
was randomly assigned a computer-generated integral
number from 1 to 100 (using a random number generating
program available at http://www.random.org, by Mads
Haahr, Distributed Systems Group, Department of Com-
puter Science, University of Dublin, and Trinity College,
Ireland). This was always done at the point of randomiza-
tion, so that no researcher could know or predict any
subsequent number. Patients who were assigned an odd
number were included in group E (embolization), and
patients who were assigned an even number in group M
(myomectomy). The researcher in charge of patient
recruitment and detailed instruction has always been dif-
ferent from the researcher accomplishing randomization.
This second doctor did not know any patient details at the
time of randomization and was only notiﬁed that the patient
met the criteria for trial entry.
Study Population
One hundred forty-nine women with uterine ﬁbroid or
ﬁbroids and unﬁnished reproductive plans were examined
from November 2001 to December 2005. All patients
entering the trial underwent gynecological examination and
abdominal and transvaginal ultrasonography (US) exami-
nation of the small pelvis, including Doppler examination
of uterus and ﬁbroids. Serum levels of follicle stimulating
hormone (FSH) luteinizing hormone (LH), and estradiol
were measured on the third day of the cycle in all patients.
Additionally, pelvic magnetic resonance imaging (MRI)
was performed (i) when clinical examination or US was
suspicious for adenomyosis or uterine sarcoma, (ii) in
virgins where vaginal US was impossible, and (iii) starting
in April 2004, in all patients before UAE. Other possible
causes of infertility were systematically investigated in
couples with primary or secondary sterility or a history of
consecutive abortions.
All patients completed a questionnaire relating to
myoma-related symptoms before the start of the thera-
peutic procedure. Each patient had to deﬁne the intensity of
symptoms on a scale from 1 to 10, where 1 = absence of
symptoms and 10 = maximal intensity of symptoms. The
following symptoms were evaluated: (i) menorrhagia and/
or hypermenorrhea, (ii) dysmenorrhea, (iii) dyspareunia,
(iv) pelvic pain, (v) dysuria and/or urinary frequency, and
(vi) pressure symptoms.
The following inclusion criteria were set: (i) US-veriﬁed
intramural ﬁbroid at least 4 cm at its largest diameter (in
the case of multiple ﬁbroids, at least one with a size of 4
cm), (ii) age\40 years, (iii) serum FSH concentration\30
IU/L (on the third day of menstrual cycle), and (iv) planned
pregnancy. Intramural ﬁbroids were deﬁned using US as a
uterine wall expansion of typical echo structure with the
prevalent part of its volume inside the myometrium.
Exclusion criteria included (i) nonintramural localiza-
tion of the main ﬁbroid (submucosal and subserous); (ii)
size of the dominant myoma[12 cm in its largest diameter
(according to US) or uterus enlarged to the size corre-
sponding to [4 months of pregnancy (according to
bimanual pelvic examination); (iii) previous myomectomy,
embolization, or hormonal therapy of ﬁbroids with GnRH
agonists or Danazol; (iv) suspected uterine sarcoma or
diffuse adenomyosis (according to US or MRI); and (v)
serious disease contraindicating gravidity.
Embolization Procedure
Patients included in group E underwent bilateral UAE. The
access for the procedure was from the right groin via the
right common femoral artery. The aim was to bilaterally
embolize the ascending branches of the uterine artery
supplying the ﬁbroid in order to achieve a complete loss of
ﬁbroid perfusion and, at the same time, leave free ﬂow in
the main stems and in cervico-vaginal branches of both
uterine arteries. We refrained from embolization of sites
displaying signiﬁcant utero-ovarian anastomoses of type III
(main ovarian blood supply arises from the uterine artery)
[7], which could not be overcome by microcatheter.
The technique of ‘‘free ﬂow embolization’’ was
employed to perform all procedures, using a 5-Fr catheter
(RUC, COOK; William Cook Europe, Bjeeverskov, Den-
mark) and always with the aid of a coaxially introduced
microcatheter (Embocath; BioSphere Medical Inc., Rock-
land, MA, USA). Trisacryl gelatin microspheres
(Embospheres; BioSphere Medical, S.A., Roissy, France)
were used for embolization in all cases. At the start of the
study (ﬁrst ﬁve patients), we chose particles 300 to 900 lm
in diameter. Later, in accordance with data published in the
literature, particles larger than 500 lm were used exclu-
sively, to prevent possible nontargeted ovarian
embolization via utero-ovarian anastomoses [8].
A single dose of antibiotics (sultamicillin; 1.5 g intra-
venously) was administered to every patient 30 min before
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h after the procedure patients were given either epidural
analgesia (10 ml of 0.5% bupivacain plus 5 lg of sufen-
tanyl in 50 ml of normal saline, administered continually at
5 to 10 ml per hour) or intravenous analgesia (5 lgo f
sufentanyl plus 0.15 mg of clonidin in 50 ml of normal
saline as a continual infusion at 5 to 10 ml per hour).
Nausea and postembolization discomfort during sub-
sequent days were treated by thiethylperazin, diclofenac,
and paracetamol. The minimal length of hospitalization
after the procedure was 48 h.
Embolization leading to bilateral occlusion of ascending
branches of urinary arteries and a complete loss of ﬁbroid
perfusion, as detected by angiography, was considered
technically successful. Dissection or spasm of uterine
arteries, adverse reaction to administered drugs, hematoma
in the groin, and other complications of angiography were
considered periprocedural complications. All procedures
were performed by the same interventional radiologist.
Myomectomy
The myomectomy procedure was always initiated with
hysteroscopy: a ﬁnding of a submucous ﬁbroid of type 0 or
type I (according to the classiﬁcation of European Society
for Hysteroscopy) would eliminate the relevant patient
from the study. Hysteroscopy was followed by laparoscopy
and the access for myomectomy was chosen according to
predeﬁned criteria. Open myomectomy (OM) was pre-
ferred when a ﬁbroid was larger than 8 cm, in the case of a
ﬁnding of multiple intramural ﬁbroids, and in the case of a
very unfavorable localization of a ﬁbroid (e.g., in uterine
edges reaching the pelvic wall or deep in the posterior
uterine wall reaching the insertions of sacro-uterine liga-
ments). In all other cases myomectomy was performed by
laparoscopy. The suture of the uterine wall defect required
after myoma enucleation was performed using atraumatic
stitches in two layers (vicryl 2/0, polyglactin 910; Ethicon,
Brussels, Belgium). Myomectomy was also covered by a
single dose of antibiotics (sultamicillin, 1.5 g i.v. 30 min
before the procedure), by the corresponding protocol of
continuous intravenous analgesia (sufentanyl plus clonidin
for the ﬁrst 24 h after the procedure), and by the same
symptomatic therapy (antiemetics, antipyretics, analgesics)
such as UAE. The minimal length of hospital stay was 48 h
after LM and 120 h (5 days) after OM.
Myomectomy was evaluated as successful when all
detectable ﬁbroids larger than 4 cm were completely
removed. The following were considered to be periopera-
tive complications: (i) injury of organs in the abdominal
cavity (fallopian tube, ovaries, urinary bladder, intestines)
or major pelvic vessels, (ii) blood loss exceeding 1000 ml,
(iii) unexpected penetration of the uterine cavity (in women
in whom ﬁbroid prominence in the cavity was not previ-
ously detected by hysteroscopy), (iv) unplanned conversion
from LM to laparotomy (during myoma enucleation), and
(v) early reoperation because of uterine bleeding, hemo-
peritoneum, or hematoma. The same two surgeons
performed all myomectomies.
Follow-up
The occurrence of the following early postoperative com-
plications were monitored during the ﬁrst 30 days: fever,
signs of pelvic infection, severe vaginal bleeding, severe
pain not responsive to analgesics, prolonged hospital stay
([48 h after UAE, 72 h after LM, and[144 h after OM),
the necessity for antibiotics or blood transfusion, rehospi-
talization, allergic reactions, wound complications after
myomectomy, ischemic phenomena after UAE, surgical
intervention due to hematoma (pelvic, subfascial, retro-
peritoneal,or inguinal) or infection, thromboembolic
complications, and hysterectomy.
Patients were examined (clinically and using ultraso-
nography) 1 month and 6 months postprocedurally and
subsequently every 6 months. The levels of FSH, LH, and
estradiol (on the third day of the cycle or at another time in
the case of amenorrhea) were measured and myoma-related
symptoms were again evaluated (the same questionnaire) 6
months after the procedure. The FSH level was monitored
in the subsequent course of follow-up in women with signs
of ovarian failure. Patients were examined immediately in
the case of difﬁculties, complications, or signs of
pregnancy.
The following late complications were assessed more
than 30 days after the procedure: (i) signs of uterine
infection or sepsis; (ii) permanent or transient signs of
ovarian failure (clinical, i.e., amenorrhea not related to
pregnancy, with or without vasomotor symptoms of men-
opause, requiring hormone replacement therapy [HRT]; or
laboratory, in the case of FSH increase by[5 IU/L, com-
pared to pretreatment values); (iii) ischemic phenomena
after UAE; (iv) chronic pelvic pain or dyspareunia; (v)
sudden severe uterine bleeding; (vi) chronic malodorous
vaginal discharge; (vii) loss of libido; (viii) emergency
myomectomy or hysterectomy; (ix) vaginal ﬁbroid expul-
sion; and (x) uterine rupture.
Great emphasis was placed on ultrasonographical scan
of the uterus 6 months after the procedure. The following
outcomes were evaluated as favorable, with regard to
planned gravidity: (i) absence of a ﬁbroid larger than 5 cm
or a ﬁbroid deforming the uterine cavity and (ii) absence of
a hematoma or thinning of the myometrium in place of
previous myomectomy. MRI was performed 6 months after
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(all patients starting from April 2004) and also in patients
who showed no sign of a ﬁbroid decrease by US. The main
beneﬁt of MRI in these patients was conﬁrmative deter-
mination of ﬁbroid reperfusion or its insufﬁcient infarction.
Reproductive Follow-up and Reinterventions
All patients with reproductive plans were recommended to
wait for at least 6 months after the therapy. Women with a
history of infertility who had a favorable outcome of a US
uterus scan 6 months after the procedure were referred to a
center of assisted reproduction to undergo causal infertility
treatment (according to associated factors), including in
vitro fertilization (IVF). History of reproductive attempts
and results of all patients were systematically recorded
during regular checkups (every 6 months). In the case of
pregnancy, prenatal monitoring and delivery at our hospital
were offered to all patients. The type of delivery and
possible indications for operative delivery were subjected
to standard rules: cesarean section was not primarily indi-
cated (only if other indications were also present) except
for cases where persisting ﬁbroid formed an obstetric
obstruction and in patients who underwent intrauterine
penetration during myomectomy.
Secondary myomectomy was recommended in the case
of undetectable ﬁbroid shrinkage at 6 months after UAE
and/or in the case of a persisting ﬁbroid [5 cm. Similar
reintervention was recommended anytime later (except
during pregnancy) when ﬁbroid regrowth after UAE (over
5 cm) or recurrent ﬁbroid [5 cm after myomectomy was
detected. The intervals between checkups after surgical
reintervention were also 6 months, and patients were rec-
ommended to delay their pregnancy plans for at least
another 6 months.
Analysis of the Results
The results were analyzed on an intent-to-treat basis. For
statistical comparison of qualitative parameters from both
groups (e.g., rehospitalization: yes or no), chi-square test
and Fischer’s test were used. For comparison of quantita-
tive parameters (e.g., FSH level), Student’s t-test and
Mann-Whitney test were used. p\0.05 was determined to
be statistically signiﬁcant.
Results
Twenty-one patients (15.4%) of 149 refused to participate
in the trial and 7 patients were excluded from the study
based on the elimination criteria; the remaining 121 women
were randomized into one of the two groups (58 for UAE
and 63 for myomectomy) and they underwent appropriate
therapy (Table 1). Of this count, 120 patients have ﬁnished
a 6-month follow-up and 3 patients have dropped out of the
trial: 1 patient did not turn up for the checkup at 6 months
after myomectomy and 2 patients did not turn up at 12
months after UAE.
Of the total number of 121 patients, 110 patients were
symptomatic (90.9%). The mean age of women was 32.4
and 32.0 years in groups E and M, respectively. Sixty-six
patients were nulligravidae (54.5%), 35 were sterile
(28.9%; 11 in group E and 24 in group M; p\0.05), 18
had miscarried in the past (14.9%), and 51 had another
subfertility factor other than myoma (42.1%). Mean FSH
levels before the procedure were 6.98 ± 2.9 IU/L in group
E and 6.73 ± 1.9 IU/L in group M. Six patients had a FSH
value [10 IU/L before embolization, and four women
before myomectomy. Except for the rate of sterility, there
were no statistically signiﬁcant differences in any afore-
mentioned factors or in other entry parameters (size of
dominant ﬁbroid, number of ﬁbroids) between the two
groups. A detailed summary of US scan ﬁndings prior to
both procedures is given in Table 2.
Periprocedural results are shown in Table 3. The rate of
technical failures was about 10% in both groups. Six
patients were embolized unilaterally (four due to atypical
branching or spasms of uterine arteries not responding to
vasodilators and two because of large utero-ovarian anas-
tomoses). In ﬁve women myomectomy was incomplete due
to unfavorable localization, resulting in the retention of a
ﬁbroid larger than 4 cm. Forty-two (67%) myomectomies
of 63 were performed by LM. The frequency of laparo-
conversions, i.e., myomectomies started by LM which had
to be completed as an open surgery because of complica-
tions (i.e., bleeding and/or difﬁcult tumor enucleation from
the uterus), was 4.5%. The following complications have
occurred: in group E, one case of artery dissection and
three cases of uterine artery spasms; and in group M, three
myomectomies with unexpected intrauterine penetration
and two nonelective laparoconversions.
There were no signiﬁcant differences in most monitored
parameters of early postprocedural results between the two
groups (Table 4). The average length of hospitalization and
postoperative recovery were signiﬁcantly longer and the
mean serum C-reactive protein concentration was signiﬁ-
cantly higher in the group of women treated by surgery.
There were no signiﬁcant differences in the frequency of
early complications between the two groups. All these
complications can be considered as mild or moderately
serious. It was the febrile status in most cases which
required therapy with antibiotics (eight patients in group E,
ﬁve patients in group M). After UAE 1 patient required a
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123Table 1 Flowchart of 142 patients (pt) eligible (according to inclusion criteria) to enter the trial
Pt no. Pt initials Year of birth Date of randomization Randomized into group Date of procedure Type of procedure
1 Z.I. 1969 2.11.2001 E 20.11.2001 UAE
2 M.H. 1967 2.11.2001 E 22.11.2001 UAE
— K.S. 1965 — Refused — —
3 L.N. 1973 7.12.2001 M 9.1.2002 OM
4 D.D. 1965 14.12.2001 E 24.1.2002 UAE
5 D.K. 1964 11.1.2002 M 21.2.2002 OM
— J.B. 1973 — Refused — —
6 M.M. 1976 8.2.2002 E 28.3.2002 UAE
— B.C. 1970 — Refused — —
7 M.L. 1974 15.3.2002 M 11.4.2002 OM
8 D.L. 1973 22.3.2002 M 15.4.2002 OM
9 V.H. 1976 22.3.2002 E 3.5.2002 UAE
10 K.S. 1968 12.4.2002 M 22.5.2002 LM
— P.K. 1964 — Refused — —
— M.P. 1976 — Refused — —
11 M.M. 1972 31.5.2002 M 4.7.2002 OM
— L.H. 1977 — Refused — —
12 L.B. 1971 21.6.2002 M 7.8.2002 OM
13 D.M. 1975 6.9.2002 E 11.10.2002 UAE
14 E.M. 1976 13.9.2002 E 15.10.2002 UAE
15 M.K. 1973 27.9.2002 M 27.11.2002 OM
16 J.C. 1974 4.10.2002 E 14.11.2002 UAE
17 L.S. 1975 18.10.2002 M 27.11.2002 LM
18 A.H. 1970 25.10.2002 M 16.12.2002 OM
19 I.K. 1970 25.10.2002 E 21.11.2002 UAE
— H.S. 1966 — Refused — —
20 M.K. 1975 13.12.2002 M 22.1.2003 OM
21 M.C. 1966 20.12.2002 E 9.1.2003 UAE
22 D.H. 1976 20.12.2002 M 28.1.2003 LM
23 D.V. 1967 10.1.2003 E 30.1.2003 UAE
24 J.B. 1971 24.1.2003 E 6.3.2003 UAE
— S.B. 1968 — Refused — —
25 V.H. 1970 7.2.2003 E 20.3.2003 UAE
26 M.O. 1967 21.2.2003 M 2.4.2003 OM
27 I.T. 1968 28.2.2003 M 14.5.2003 OM
28 H.A. 1964 28.3.2003 E 30.4.2003 UAE
29 L.V. 1969 4.4.2003 E 7.5.2003 UAE
30 J.M. 1963 25.4.2003 M 3.6.2003 OM
31 M.K. 1974 25.4.2003 E 19.5.2003 UAE
32 L.T. 1968 2.5.2003 M 17.6.2003 OM
33 S.B. 1971 2.5.2003 E 29.5.2003 UAE
34 E.T. 1968 23.5.2003 E 3.7.2003 UAE
35 B.P. 1973 13.6.2003 M 9.9.2003 OM
36 L.K. 1974 13.6.2003 E 3.7.2003 UAE
— I.S. 1964 — Refused — —
37 M.S. 1966 10.10.2003 M 26.11.2003 LM
38 M.H. 1964 24.10.2003 E 4.12.2003 UAE
— A.H. 1965 — Refused — —
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Pt no. Pt initials Year of birth Date of randomization Randomized into group Date of procedure Type of procedure
39 K.K. 1975 19.12.2003 M 10.2.2004 LM
40 L.J. 1967 19.12.2003 E 9.1.2004 UAE
41 I.F. 1971 9.1.2004 E 23.1.2004 UAE
42 D.L. 1977 16.1.2004 M 17.2.2004 LM
43 J.V. 1977 16.1.2004 E 17.2.2004 UAE
44 E.S. 1972 30.1.2004 M 2.3.2004 LM
45 R.K. 1966 6.2.2004 E 5.3.2004 UAE
46 J.H. 1972 13.2.2004 E 12.3.2004 UAE
47 M.M. 1967 13.2.2004 M 23.3.2004 LM
48 M.Z. 1970 20.2.2004 E 12.3.2004 UAE
49 E.S. 1970 5.3.2004 M 20.4.2004 LM
50 M.M. 1965 12.3.2004 M 20.4.2004 OM
51 K.K. 1968 12.3.2004 E 2.4.2004 UAE
52 D.M. 1968 19.3.2004 M 21.4.2004 OM
53 N.V. 1969 19.3.2004 M 21.4.2004 LM
54 M.T. 1970 26.3.2004 M 8.6.2004 LM
55 I.S. 1966 26.3.2004 E 29.4.2004 UAE
— E.Z. 1971 — Refused — —
56 M.P. 1974 23.4.2004 M 7.7.2004 LM
57 E.K. 1972 23.4.2004 E 14.5.2004 UAE
58 P.S. 1967 7.5.2004 M 19.7.2004 OM
59 L.D. 1974 14.5.2004 M 21.7.2004 LM
60 J.S. 1968 14.5.2004 E 11.6.2004 UAE
61 H.K. 1965 21.5.2004 M 7.9.2004 OM
62 M.M. 1972 28.5.2004 M 12.10.2004 LM
63 A.M. 1970 28.5.2004 M 9.11.2004 LM
64 V.H. 1978 31.5.2004 E 11.6.2004 UAE
65 K.W. 1970 4.6.2004 E 9.7.2004 UAE
— L.S. 1975 — Refused — —
66 K.H. 1973 18.6.2004 E 20.8.2004 UAE
67 E.B. 1983 25.6.2004 E 20.8.2004 UAE
68 K.F. 1968 2.7.2004 E 9.9.2004 UAE
69 M.R. 1973 9.9.2004 M 16.11.2004 LM
70 M.H. 1967 9.9.2004 E 1.10.2004 UAE
— J.P. 1976 — Refused — —
— D.R. 1965 — Refused — —
71 K.F. 1976 23.9.2004 M 29.11.2004 LM
72 P.C. 1975 23.9.2004 E 22.10.2004 UAE
73 P.P. 1972 30.9.2004 E 22.10.2004 UAE
74 B.S. 1972 7.10.2004 M 19.1.2005 LM
75 P.H. 1969 14.10.2004 E 3.11.2004 UAE
76 J.L. 1979 14.10.2004 M 26.1.2005 LM
77 J.E. 1968 21.10.2004 M 27.1.2005 LM
78 L.A. 1969 21.10.2004 E 19.11.2004 UAE
79 M.D. 1975 4.11.2004 M 2.2.2005 LM
80 M.R. 1972 11.11.2004 E 10.12.2004 UAE
81 M.Z. 1966 18.11.2004 M 17.2.2005 LM
82 S.Z. 1971 9.12.2004 M 17.2.2005 LM
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Pt no. Pt initials Year of birth Date of randomization Randomized into group Date of procedure Type of procedure
83 H.S. 1968 16.12.2004 E 21.1.2005 UAE
84 M.S. 1974 6.1.2005 E 18.2.2005 UAE
— E.K. 1965 — Refused — —
— S.D. 1970 — Refused — —
85 L.L. 1972 27.1.2005 E 18.3.2005 UAE
86 L.M. 1972 3.2.2005 M 21.3.2005 LM
87 I.C. 1970 17.2.2005 M 23.3.2005 LM
88 P.Z. 1971 24.2.2005 E 8.4.2005 UAE
89 M.K. 1969 24.2.2005 M 11.4.2005 LM
— M.T. 1975 — Refused — —
90 H.K. 1967 3.3.2005 M 26.4.2005 OM
91 B.Z. 1974 10.3.2005 E 6.5.2005 UAE
92 M.K. 1965 24.3.2005 M 4.5.2005 LM
93 A.G. 1977 31.3.2005 M 16.5.2005 LM
94 L.P. 1972 7.4.2005 M 17.5.2005 LM
95 L.H. 1977 7.4.2005 M 18.5.2005 OM
96 J.K. 1976 14.4.2005 E 13.5.2005 UAE
97 M.L. 1976 21.4.2005 M 23.5.2005 LM
— H.V. 1965 — Refused — —
98 M.K. 1974 12.5.2005 M 6.6.2005 LM
99 P.L. 1978 26.5.2005 E 1.8.2005 UAE
100 E.P. 1971 23.6.2005 E 1.8.2005 UAE
101 K.K. 1977 30.6.2005 M 7.9.2005 LM
102 L.F. 1969 14.7.2005 E 21.9.2005 UAE
— E.S. 1966 — Refused — —
103 J.R. 1980 8.9.2005 M 26.9.2005 LM
104 E.H. 1972 8.9.2005 E 23.9.2005 UAE
105 O.S. 1967 15.9.2005 M 5.10.2005 LM
106 I.K. 1970 15.9.2005 M 12.10.2005 LM
— H.A. 1966 — Refused — —
107 P.P. 1966 22.9.2005 E 14.10.2005 UAE
108 M.A. 1977 29.9.2005 M 26.10.2005 LM
109 E.Z. 1973 29.9.2005 M 2.11.2005 LM
110 I.S. 1979 29.9.2005 M 2.11.2005 LM
111 D.M. 1967 6.10.2005 E 21.10.2005 UAE
112 J.B. 1967 6.10.2005 M 2.11.2005 LM
113 A.G. 1983 13.10.2005 M 9.11.2005 OM
114 J.P. 1973 13.10.2005 E 15.11.2005 UAE
115 S.S. 1969 20.10.2005 M 16.11.2005 LM
116 H.D. 1974 27.10.2005 M 1.12.2005 LM
117 L.B. 1973 27.10.2005 E 2.12.2005 UAE
— D.V. 1976 — Refused — —
118 K.K. 1970 10.11.2005 E 2.12.2005 UAE
119 M.J. 1972 10.11.2005 M 1.12.2005 LM
120 R.L. 1977 10.11.2005 E 9.12.2005 UAE
121 D.R. 1975 24.11.2005 E 9.12.2005 UAE
Note. LM, laparoscopic myomectomy; OM, open myomectomy; UAE, uterine artery embolization. Dates given as day.month.year
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123prolonged hospital stay due to severe vaginal bleeding
(treated by pharmacotherapy), one patient developed a rash
as a probable reaction to analgesics, and one woman was
treated for postpuncture headache after epidural anesthesia.
Additionally, a subcutaneous hematoma of approximately
5 cm developed in one woman at the site of puncture in the
right groin and was managed by conservative therapy.
After myomectomy two patients (one after LM and one
after OM) required transfusion due to severe anemia, one
woman developed a urinary tract infection, and one woman
a wound infection. One patient underwent surgical evacu-
ation of subfascial hematoma 1 day after OM.
Table 2 Ultrasound ﬁndings for 121 patients prior to uterine artery embolization (UAE) or myomectomy
UAE (n = 58) Myomectomy (n = 63) p
Average size of dominant ﬁbroid, mm ± SD (range) 62.3 ± 19.1 (42–107) 59.8 ± 16.5 (41–110) NS
a
No. women with myoma[80 mm 8 (13.8%) 7 (11.1%) NS
b
No. myomas[2 cm ± SD (range) 1.95 ± 1.8 (1–8) 1.84 ± 2.1 (1–16) NS
a
No. women with Solitary myomas 39 (67.2%) 40 (63.5%) NS
b
2–5 ﬁbroids 15 (25.9%) 21 (33.3%) NS
b
[5 ﬁbroids 4 (6.9%) 2 (3.2%) NS
c
Uterine cavity deviated by ﬁbroid(s) 30 (51.7%) 22 (34.9%) NS
b
Note. NS, nonspeciﬁc difference; SD, standard deviation. Tested by:
a Mann-Whitney test;
b chi-square test;
c Fisher’s test
Table 3 Periprocedural evaluation
UAE (n = 58) Myomectomy (n = 63) P
Technical success 52 (89.7%) 58 (92.1%) NSb
Average time of procedure, min ± SD (range) 59.2 ± 23.1 (30–140) 108.9 ± 27.7 (54–173) \0.0001
a
Fluoroscopy time, min ± SD (range) 16.8 ± 6.3 (5–33) —
No. women with utero-ovarian anastomoses 25 (43.1%) —
Average perioperative blood loss, ml ± SD (range) — 296.0 ± 122.6 (100–700)
Type of analgesia 38 EDA/20 IVA 63 IVA
Complications 4 (6.9%) 5 (7.9%) NS
c
Note. UAE, uterine artery embolization; NS, nonspeciﬁc difference; SD, standard deviation; EDA, epidural analgesia; IVA, intravenous
analgesia. Tested by:
a Mann-Whitney test;
b chi-square test;
c Fisher’s test
Table 4 Early postprocedural results (from day 1 to day 30 after procedure)
UAE (n = 58) Myomectomy (n = 63) P
Average hospital stay, h ± SD (range) 60.2 ± 32.3 (36–216) 86.1 ± 40.4 (48–192) \0.0001
a
Prolonged hospital stay
* 9 (15.5%) 6 (9.5%) NS
b
Hospital stay[7 days 1 (1.7%) 3 (4.8%) NS
c
Readmissions to hospital 2 (3.4%) 1 (1.6%) NS
c
Febrile morbidity 7 (12.1%) 7 (11.1%) NS
b
Day 2 serum CRP, mg/L ± SD (range) 23.8 ± 27.3 (3–168) 36.9 ± 28.1 (6–137) \0.0001
a
Need for antibiotics 8 (13.8%) 6 (9.5%) NS
b
Necessity for transfusion 0 2 (3.2%) NS
c
Recovery period, days ± SD (range) 11.9 ± 5.9 (3–30) 22.1 ± 12.3 (7–65) \0.0001
a
Disability[2 wk 13 (22.4%) 36 (57.1%) \0.0001
b
Complications 12 (20.7%) 10 (15.9%) NS
b
Note. UAE, uterine artery embolization; NS, nonspeciﬁc difference; SD, standard deviation; CRP, C-reactive protein. Tested by:
a Mann-
Whitney test;
b chi-square test;
c Fisher’s test
*Longer hospital stay than usual (i.e., more than 48 h after UAE, 72 h after laparoscopic myomectomy, and 144 h after open myomectomy)
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123Tables 5 and 6 summarize late clinical results and
results of imaging studies at 6 months after the procedure.
The mean length of follow-up was approximately 2 years
in both groups; 81% of women after embolization and 79%
after surgery have been followed for more than 1 year, and
50% of patients in group E and 43% in group M have been
followed for at least 2 years. Both methods were similarly
effective when cumulative evaluation of all symptoms at 6
weeks after the procedure was considered. While it seemed
at preliminary evaluation of results that representation of
patients with total relief from all myoma-related symptoms
would be signiﬁcantly higher in group M, it now appears
that their number is only insigniﬁcantly higher (32 of 58
women, i.e., 55 %) in this group than after embolization
(26 of 52 women, i.e., 50%).
With respect to the main goal of the therapy (gravidity)
and trial design, both groups differed signiﬁcantly in the
frequency of reinterventions. Secondary myomectomy was
performed in 19 cases in group E: 9 by LM, 8 by lapa-
rotomy, and 2 by hysteroscopy. The mean interval from
UAE to reintervention was 12.4 months (±12.2 months;
median, 7.0 months). The persistence of a large ﬁbroid ([5
cm) at 6 months after UAE was the most frequent indica-
tion (15 cases, including 5 patients with UAE technical
failure), and in 4 cases we reintervened due to regrowth of
a ﬁbroid (see Table 5). In group M, the reintervention was
indicated only in cases of clinically signiﬁcant recurrence.
Remyomectomy was performed in two women (one by LM
and one by open surgery) at a 15- and 30-month interval
from primary therapy, respectively.
We recorded a relatively low frequency of late com-
plications. All these incidents (dyspareunia, pelvic pain,
endometritis, and one episode of metrorrhagia) after
myomectomy were regarded as mild and nonserious. No
serious or life-threatening complications have occurred
after UAE either, but in four women there were compli-
cations related to ovarian function. One patient with 6
weeks of amenorrhea had no further menopausal symp-
toms, had a normal FSH level (6.4 IU/L) at 6 months after
UAE, and is pregnant now. A transitory, but signiﬁcant
FSH elevation, to 15.0, 30.4, and 48.9 IU/L, respectively,
occurred in three women with preprocedural FSH\10 IU/
L (Table 5). One of these women suffered amenorrhea for
2 months and did not respond to progesterone, but her cycle
adjusted spontaneously. This woman has not tried to con-
ceive to date. Another two patients with FSH elevation
were clinically asymptomatic (from the time of emboliza-
tion until now, which is 53 and 35 months, respectively),
but they both underwent unsuccessful therapy for sterility,
including two and three IVF cycles, respectively, to date.
Low response to ovarian stimulation with gonadotropins
(high consumption of FSH, low number of reacting folli-
cles) and poor development of most embryos were
common for their cycles.
Table 5 Late postprocedural results
UAE (n = 58) Myomectomy (n = 62) P
Mean follow-up, mo ± SD (range) 26.2 ± 14.2 (6–55) 23.7 ± 13.9 (6–54) NS
a
Relief from symptoms* 88.5% (46/52) 87.9% (51/58) NS
b
6 mo after procedure Serum FSH, IU/L ± SD (range) 7.89 ± 6.0 (4.0–48.9) 6.49 ± 2.0 (3.6–12.3) NS
a
FSH[10 IU/L 8 (13.8%) 2 (3.2%) \0.05
c
Signiﬁcant elevation of FSH
  3 (5.2%) 0 NS
c
Regrowth or recurrence of ﬁbroid(s) 6 (10.3%) 5 (8.1%) NS
b
Reinterventions 19 (32.8%) 2 (3.2%) \0.0001
b
Reinterventions for regrowth or recurrence of ﬁbroid(s) 4 (6.9%) 2 (3.2%) NS
c
Complications 8 (13.8%) 5 (8.1%) NS
b
Note. UAE, uterine artery embolization; NS, nonspeciﬁc difference; SD, standard deviation. Tested by:
a Mann-Whitney test;
b chi-square test;
c
Fisher’s test
*Lower sum of six followed symptoms at 6 months after procedure than preprocedurally (based on the questionnaire)
  At least 5 IU/L increase at 6 months after procedure (compared with preprocedural level)
Table 6 Results of imaging studies 6 months after uterine artery
embolization (UAE)
Mean shrinkage of diameter of
dominant ﬁbroid on US (58 patients)
31.7%
Mean shrinkage of volume of
dominant ﬁbroid on MRI*
58.7%
Mean volume of dominant
ﬁbroid on MRI*
69 cm
3
(pre-UAE: 166 cm
3)
Partial infarction of dominant
ﬁbroid on MRI*
28.9% (11 / 38)
No infarction of dominant
ﬁbroid on MRI*
2.6% (1 / 38)
*Calculated from only 38 patients with both (pre- and post-UAE)
MRI scans
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123Overall there were eight patients with a FSH concen-
tration [10 IU/L at 6 months after UAE (including four
women with a pre-UAE value[10 IU/L and three with an
increase of[5 IU/L) and two patients with FSH[10 IU/L
at 6 months after myomectomy (including one with pre-
procedural FSH [ 10 IU/L and no case of signiﬁcant
increase). No patients had climacteric vasomotor symp-
toms and no patient required HRT. Two patients
complained of temporarily decreased sexual appetence
after embolization (this improved within 12 months): 1 of
them in connection with noticeable hypomenorrhea and the
other patient in connection with the feeling of ‘‘vaginal
dryness.’’ No case of uterine rupture, urgent hysterectomy
or other emergency surgery, or hospitalization for late
complications after embolization or myomectomy has
occurred in the whole cohort to date.
Existing reproductive and ﬁrst perinatal results are
summarized in Fig. 1 and Table 7. From the limited cohort
of patients who have already tried to conceive (26 after
UAE and 40 after myomectomy), 13 from group E (mean
age, 32.8 years; range, 22 to 40 years) and 31 from group
M (mean age, 34.3 years; range, 27–42 years) have already
become pregnant. Four women after embolization and one
patient after myomectomy have already become pregnant
two times; one woman after myomectomy gave birth to
twins (after IVF). The mean interval between the procedure
and gravidity was 18 and 13 months in groups E and M,
respectively. This difference could be partially inﬂuenced
by the rate of secondary myomectomy in the two groups of
pregnant women: it was performed in 5 of 13 pregnant
women after UAE but in 1 only patient of 31 pregnant
patients in group M. Presenting the results in the language
of reproductive medicine, the pregnancy rate after UAE
was 50% to date, delivery rate 19%, and abortion rate 64%,
while after myomectomy the pregnancy rate was 78%,
delivery rate 48%, and abortion rate 23%. The differences
in all these parameters were statistically signiﬁcant
(p\0.05, v
2 test). Relative risk (RR) of women treated
with UAE not to get pregnant was 2.22 (95% conﬁdence
interval, 1.11\RR\4.44); not to deliver, 1.54 (1.08\RR
\2.18); and to abort, 2.79 (1.25\RR\6.22).
Discussion
Comparison of myomectomy and UAE, two very different
therapeutic approaches, is difﬁcult and could appear mis-
leading, particularly in some parameters (invasiveness,
complication rate, reinterventions). Nevertheless, the
question of possible use of uterine ﬁbroid embolization in
young women with active reproductive plans is very
important from the point of view of gynecology and
reproductive medicine. The surgical therapy is, especially
in some patients, technically difﬁcult, invasive, and risky,
and therefore comparison of UAE with myomectomy as a
possible alternative to existing standard therapy is most
desirable [9].
There are many reports about gravidities and repro-
ductive results after embolization in the literature today
[10–15]. Surprisingly, there is an apparent nearly absolute
lack of prospective studies comparing not only myomec-
tomy and UAE, but also different ﬁbroid treatments in
relation to fertility (e.g., myomectomy with expectation).
Only four papers [16–19] compare clinical results of
embolization and myomectomy. But they are not ran-
domized studies, only one is prospective [19], and only one
is aimed at obstetrical, not just reproductive results [17].
In this study we conﬁrmed in a midterm time horizon
and in a larger cohort of patients most of the results from
our preliminary evaluation [6]. Myomectomy and emboli-
zation were comparable as far as technical success rate,
frequency of early and late complications, and symptom-
atic effectiveness are concerned. We also veriﬁed lower
invasiveness of the radiological approach compared to
myomectomy (hospital stay, recovery period, acute phase
markers). The rate of serious complications was very low
in both groups. The trial does not give the answer to the
management of large or recurrent ﬁbroids (see exclusion
criteria) but our goal was to keep the study group as
homogeneous as possible, which is always difﬁcult in
uterine ﬁbroid patients. Unlike other studies, we did not
focus on economical comparisons between the two treat-
ment methods [20], mainly because the cost of UAE is
many times higher than that of myomectomy at the site of
this study, and there are signiﬁcant differences between
open and laparoscopic myomectomy.
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Fig. 1 Reproductive results of 26 women after uterine artery
embolization (UAE) and 40 women after myomectomy. Statistical
difference between the groups (p value): pregnancy, NS
b; delivery,
\0.05
b; abortion, \0.05
b; ectopic gestation, NS
c; pregnancy termi-
nation, NS
c; pregnant now, NS
c. Tested by:
bchi-square test;
cFisher’s
test. NS, nonsigniﬁcant
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123The relatively high rate of LMs (two-thirds) might seem
surprising and it certainly does not represent a typical
picture of a broad gynecological practice. But we believe
that these patients should always be referred to centers of
reproductive surgery with experienced endoscopic sur-
geons. With respect to certain limits for LM (mentioned
under Materials and Methods), many studies have already
proved the equal safety and potency of the laparoscopic
approach in comparison to the open procedure [21, 22].
The technical failure rate of UAE was higher than the
rates reported in other studies [23, 24], mainly as a result of
the unusual or unfavorable anatomy (anastomoses to
ovarian artery) present. Another reason for the higher
failure rate could be the nature of our patient group,
comprised of young women desiring pregnancy. This
might account for a particularly careful approach to their
treatment. Only the results of the EMMY trial showed a
similar frequency of technical failures [25], but in their
case, in addition to difﬁcult anatomy, the absence of one of
the uterine arteries was the most common reason.
In accordance with our expectations, there were far
more reinterventions in the group treated by embolization
(Table 5). But these numbers do not reﬂect the frequency
of method failure or the rate of recurrence. Instead, they
seem to be the logical consequences of the different char-
acter of the two procedures (UAE leaves ﬁbroids in situ), of
the main goal of the therapy (to optimize the uterine con-
dition before planned conception), and of methods adapted
to it (speciﬁc strategy for indications of reinterventions).
The fact that in the initial study postprocedural MRI was
performed only in patients where signiﬁcant shrinkage of
ﬁbroid had not occurred (including 6 patients with unilateral
embolization only) could account for the relatively high
number of cases with at least partially maintained ﬁbroid
perfusion at 6 months after UAE (12 patients of 38 evalu-
ated; see Table 6). If we had performed this examination in
all women, including those with a good clinical response
and Doppler US evidence of infarcted ﬁbroid, this number
would have been expected to be signiﬁcantly lower.
Existing reproductive results could be partially inﬂu-
enced by the short duration of the follow-up and mainly by
theunequalnumberofpatientswhotriedtoconceiveineach
group: 40after myomectomyandonly26after embolization
(p\0.05, v
2 test). Nevertheless, the statistically signiﬁcant
differences observed in the number of successful deliveries
(19 after myoma enucleation and only 5 after UAE) and in
the number of early pregnancy losses (6 after myomectomy
and 9 after embolization; in all cases spontaneous or missed
miscarriage in the ﬁrst trimester) were in support of the
surgical approach. We can only speculate whether these
reproductive results are due to an error of small numbers,
whether they reﬂect the inﬂuence of UAE on ovarian
function, uterine perfusion, and implantation quality, or
whethertheyreﬂectadirectinﬂuenceofembolizationonthe
uterine cavity and endometrium [26–28].
The fact that the rate of abortions after UAE was higher
than 60% (in contrast with 23% after myomectomy) is the
most alarming result of the study to date, in contrast to
existing reports from other authors [10, 12, 17]. The post-
UAE abortion rate was 16.7% in the Ontario multicenter,
prospective trial (24 pregnancies in 21 women of mean age
34 years), 27% in the retrospective trial of Carpenter and
Walker (26 pregnancies; mean age of patients, 37 years),
and 24% after UAE and 15% after laparoscopic myomec-
tomy in the controlled retrospective multicenter trial of
Goldberg et al. (53 pregnancies; mean age, 38 years), but
the difference was not statistically signiﬁcant. In our cohort,
the mean age of pregnant women after UAE was lower
(32.8 years) than that of pregnant women after myomec-
tomy (34.3 years), and at the same time, it was lower than in
the aforementioned trials. The mean age of women who
aborted after embolization was only slightly higher (33.0
years), and that is why the age factor does not explain the
frequency of abortions after UAE. The abortion rate was
Table 7 Perinatal results
UAE (n = 5) Myomectomy (n = 19) p
Mean age of mothers, yr ± SD (range) 32.2 ± 4.1 (29–39) 34.4 ± 4.4 (27–42) NS
a
Mean birth weight, g ± SD (range) 3042 ± 316 (2830–3600) 3035 ± 538 (1600–3940) NS
a
Mean completed gestational weeks ± SD (range) 38.8 ± 0.6 (38–40) 37.5 ± 2.4 (31–40) NS
a
Preterm delivery (\37th week) 0 5 (26.3%) NS
b
Cesarean section 3 (60.0%) 13 (68.4%) NS
b
Postpartum hemorrhage 1 (20.0%) 0 NS
b
Perinatal hypoxia of neonate 0 0 —
Pre-eclampsia 0 2 (10.5%) NS
b
Fetal intrauterine growth restriction 0 2 (10.5%) NS
b
Note. UAE, uterine artery embolization; NS, nonspeciﬁc difference; SD, standard deviation. Tested by:
a Mann-Whitney test;
b Fisher’s test
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123expressed as a quotient of all abortions in all begun preg-
nancies, thus including two patients with terminations
in early gravidity (one termination due to extrauterine
gravidity and one termination in the eighth week of gesta-
tion). Even when excluding these two cases from the overall
abortion rate, this number would still be notably higher
(53%). On the other hand, the pregnancy success rate after
UAE is signiﬁcantly higher in our cohort (50%) than the
rate reported by Carpenter and Walker, where only 26
(33%) of 79 women conceived after embolization.
It is difﬁcult to compare obstetrical results at the
moment because only a small number of patients after
embolization have passed the ﬁrst trimester of pregnancy.
The statistical analysis did not prove any signiﬁcant dif-
ferences in any of the parameters studied between the two
groups, however, Table 6 provides an interesting summary
of existing perinatal results and complications. It is
remarkable to point out that, provided a pregnant woman
after UAE successfully passed the ﬁrst trimester, we sub-
sequently did not record any of the serious pregnancy
complications (e.g., gestational hypertension, fetal growth
retardation, malpresentation, or prematurity) repeatedly
described in other trials [10, 12, 17].
At the beginning of this trial we asked ourselves the
question whether the less invasive method of ﬁbroid
embolization in women with reproductive plans is as
effective and safe as myomectomy. After more than 4 years
of the trial duration it can be concluded that both methods
are comparable in terms of technical success rate, safety,
and symptomatic efﬁcacy. UAE is a less invasive
approach, but also, as it appears at this midterm following,
it is less deﬁnitive if the aim is to maximally eradicate
ﬁbroids before gravidity. For a deﬁnitive case comparison
of reproductive and perinatal results we need to analyze
more patients who try to conceive after the procedures and
use a longer follow-up. However, the existing results
clearly indicate that myomectomy is a method with a
greater chance of success in women who plan to get
pregnant early after the procedure.
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